News & Updates
Filter by Specialty:
Artificial pancreas yields good results in type 2 diabetes patients
A fully closed-loop insulin delivery system, also known as artificial pancreas, helps improve the management of type 2 diabetes in adults, increasing the time spent in target glucose range by 8 hours per day without promoting hypoglycaemic events as compared with standard insulin therapy, as reported in a study.
Artificial pancreas yields good results in type 2 diabetes patients
17 Jan 2023
Lebrikizumab–topical corticosteroid combo improves outcomes in moderate-to-severe AD
Treatment with lebrikizumab, when combined with low- to mid-potency topical corticosteroid (TCS), helps reduce disease severity in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD), with a safety profile consistent with that reported in previous AD studies, according to the phase III ADhere trial.
Lebrikizumab–topical corticosteroid combo improves outcomes in moderate-to-severe AD
16 Jan 2023
PFS in relapsed/refractory CLL/SLL: Zanubrutinib triumphs over ibrutinib
The second-generation BTK* inhibitor zanubrutinib was superior to the standard-of-care ibrutinib in improving progression-free survival (PFS) among patients with relapsed/refractory chronic lymphocytic leukaemia (R/R CLL) or small lymphocytic lymphoma (SLL), according to results of the phase III ALPINE trial presented at ASH 2022.
PFS in relapsed/refractory CLL/SLL: Zanubrutinib triumphs over ibrutinib
15 Jan 2023
Etanercept biosimilar demonstrates long-term safety, efficacy in rheumatoid arthritis
YLB113, a biosimilar of the reference product etanercept, appears to be safe for long-term treatment of patients with rheumatoid arthritis, with efficacy sustained for up to 96 weeks, according to a study. Notably, the biosimilar is associated with fewer cases of injection-site reactions and injection-site erythema compared with the reference.